-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 20 March 2025 | Drug Target Review | Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 14 March 2025 | Drug Target Review | Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 13 March 2025 | Drug Target Review | A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals. Protecting the heart during cancer treatmentCancer treatments, particularly chemotherapy, often lead to severe cardiovascular complications that substantially impact patient health and quality of life.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 12 March 2025 | Drug Target Review | Researchers have discovered a breakthrough method to silence MRSA’s drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs. A study from the Nanjing University School of Life Sciences has revealed a promising new strategy for combating antibiotic-resistant bacterial infections.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 10 March 2025 | Drug Target Review | Cornell researchers have discovered how transposons, or ‘jumping genes,’ insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 7 March 2025 | Drug Target Review | Google has introduced an AI-powered ‘co-scientist’ designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets. Google’s newly introduced AI co-scientist, powered by Gemini 2.0, is designed to assist researchers by generating hypotheses, designing experiments, and analysing complex datasets.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 6 March 2025 | Drug Target Review | Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments. A study from Uppsala University, published in Nature Communications, reveals a new computational method capable of searching through an astonishing 10 sextillion (10²²) potential drug molecules.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 5 March 2025 | Drug Target Review | Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy. Insilico Medicine, a biotechnology company leveraging generative artificial intelligence (AI), has announced a significant breakthrough in cancer therapeutics.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 4 March 2025 | Drug Target Review | Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments. Scientists at the VCU Massey Comprehensive Cancer Centre have revealed a pioneering combination treatment strategy that increases the death of acute myeloid leukaemia (AML) cells.
-
1 month ago | 
drugtargetreview.com | Carrie Haslam
Posted: 3 March 2025 | Drug Target Review | York University researchers have discovered a genetic mutation in the TRAF1 protein that dramatically reduces inflammation, offering a potential breakthrough in rheumatoid arthritis treatment. In a significant scientific breakthrough, researchers at York University’s Faculty of Health have discovered a genetic mutation that could transform treatment approaches for rheumatoid arthritis and other inflammatory diseases.
